OpenAI Acquires Biotech Startup Orchestra Bio to Strengthen Its Life-Sciences AI
OpenAI has acquired Orchestra Bio, a four-year-old San Francisco AI biotech software startup, the company announced on 20 October. Terms were not disclosed; Orchestra had reportedly raised around $20 million from backers including Andreessen Horowitz, Atria and 8VC.
OpenAI has acquired Orchestra Bio, a four-year-old San Francisco AI biotech software startup, the company announced on 20 October. Terms were not disclosed; Orchestra had reportedly raised around $20 million from backers including Andreessen Horowitz, Atria and 8VC. Orchestra builds AI agents that help biotech companies manage drug-discovery operations, from tracking finances to resolving clinical-trial scheduling issues. OpenAI is adding Orchestra's team and technology to Rosalind, its AI model for life-sciences research, and the Rosalind Workbench tool for planning experiments and analysing results. OpenAI says Rosalind customers already include Moderna and Novo Nordisk.
Source: TechCrunch, 20 Oct 2026
Tags: OpenAI, Orchestra Bio, Acquisition, Biotech, AI Agents, a16z
TechCrunch
techcrunch.com
More from the newsroom
All news
DeepSeek Wrapping Up $15 Billion Funding Round Backed by Tencent and CATL
Chinese AI startup DeepSeek is wrapping up a funding round of about 100 billion yuan (around $15 billion), roughly double its original 50 billion yuan target, according to a Reuters report published on 22 October. Battery maker CATL and Tencent were among the biggest investors in the round.
Year-Old AI Lab Flapping Airplanes Raises $1 Billion Series A at Reported $6 Billion Valuation
Flapping Airplanes, an AI research lab founded about a year ago, has announced a $1 billion Series A round co-led by Index Ventures and Lux Capital, at a reported $6 billion valuation.
Slush 2026 — Helsinki
Slush, the world's most founder-focused startup event, returns to Helsinki on 18–19 November 2026 at Messukeskus, with an Investor Day and founders' programme on 17 November.